Treatment for metastatic colorectal cancer

SUMMARY

Colorectal cancer is the third most diagnosed cancer and fourth most common cause of death worldwide, metastasis being the cause of about 90% of deaths. Team Stein has identified two FDA approved drugs that combined robustly inhibit the metastasis of colon cancer. They have initiated a first phase II clinical trial for one of the drugs – and are aiming at initiating a second phase II clinical trial for combinatorial therapies for colorectal cancer (CRC). An option contract has been negotiated with a biotech company, which also includes an option for an industry partnership with the Stein Team.

PROJECT ACHIEVEMENTS DURING & AFTER SPARK

- One patent granted, several patents pending
- First preclinical developmental steps & POC completed
- Phase II mono-therapy clinical study is running
- Ongoing licensing negotiations & planned industry partnership